Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks

VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2012-07, Vol.18 (14), p.3719-3721
Hauptverfasser:	EBOS, John M. L, PILI, Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Biological and medical sciences Cell Proliferation Clinical Trials as Topic Endothelial Cells - cytology Humans Medical sciences Mice Neoplasms - therapy Pharmacology. Drug treatments Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-12-1459